Clinical Trial

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2 trial Safety Lead-in trial conducted in 3 cohorts of patients. A safety lead-in study of the impact of adding the Repurposed Drugs a third agent will be conducted prior to opening enrollment into the compassionate use study. All patients enrolled in the safety lead-in study may continue long-term treatment under this protocol without interruption of dosing.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-10-25; most recent amendment 2025-12-02.
Trial Details
NCT Number NCT05106127
Lead Sponsor Evergreen Therapeutics, Inc.
Conditions Advanced Endometrial Cancer
Enrollment 28 participants
Start Date 2026-08
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-12-08